Inflammation may predict success of targeted cancer therapy
NCT ID NCT07241403
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 698 people with metastatic colorectal cancer to see if chronic inflammation changes how well bevacizumab (a targeted therapy) plus chemotherapy works. Researchers measured inflammation markers in the blood and analyzed immune proteins to find clues about treatment resistance and survival. The goal was to better understand who benefits from this combination therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients with metastatic colorectal cancer will benefit most from bevacizumab combined with chemotherapy.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove cause and effect, and the findings may not apply to all patients or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEVACIZIMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The second hospital of Nanchang university
Nanchang, Jiangxi, 330006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?